Neuronetics, Inc. $STIM

What the company doesAI summary of filing

Neuronetics, Inc. is a revenue-generating medical device company that develops and commercializes the NeuroStar Advanced Therapy System, a non-invasive, FDA-cleared medical device that uses transcranial magnetic stimulation to treat major depressive disorder, obsessive-compulsive disorder, and anxious depression. The company generates revenue from capital sales of NeuroStar systems, recurring treatment sessions, and service contracts, as well as from operating Greenbrook, a wholly owned subsidiary comprising 93 treatment centers across the United States that provide NeuroStar therapy and SPRAVATO (esketamine) treatments. For the year ended December 31, 2025, Neuronetics generated $149.2 million in revenues, representing 99% growth compared to the prior year, with the majority of revenues derived from clinic operations and recurring treatment sessions. The company also markets its products internationally through distributors, with an exclusive distribution agreement in Japan. [10-K 2026-03-17]

Segments: NeuroStar Advanced Therapy System (capital equipment and treatment sessions), Greenbrook Treatment Centers (clinic operations), SPRAVATO therapy (esketamine), International distribution